Fig. 1: Selection process for real-world Eligible Cohort. | Blood Cancer Journal

Fig. 1: Selection process for real-world Eligible Cohort.

From: KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Fig. 1

Collection of patient-level data from clinical sites, the Connect MM Registry, and external research databases, and a description of the selection process for the Eligible RRMM cohort in the KarMMa-RW study. *Baseline was defined as when patients became refractory to their last regimen. †Across all ide-cel target doses in the KarMMa study (ClinicalTrials.gov: NCT03361748); at the data cutoff of 30 October 2019, 58 patients (45.3%) had discontinued from the study, 31 (24.2%) due to death, 26 (20.3%) due to study withdrawal, and 1 (0.8%) lost to follow-up. ‡Overall, 108 patients (56.8%) discontinued from the study, all due to death. §Numbers (ranges) of matched patients from 30 imputed datasets. COTA denotes the COTA real-world evidence database, ECOG Eastern Cooperative Oncology Group, GRN Guardian Research Network, RRMM relapsed and refractory multiple myeloma.

Back to article page